1026 / 1851
PACIFIC PD-L1 Phase III Trial
Consolidative therapy with Durvalumab vs Placebo
Chemoradiotherapy
Placebo
MEDI 4736 – Durvalumab
(PD-L1 inhibitor)
Planned accrual: 702 pts, >100 sites
Endpoints: PFS, OS
Future Perspectives…